Opinion|Videos|December 9, 2025
Novel Pharmacotherapies and NCCN Guideline Recommendations
Explore the evolving landscape of desmoid tumor treatments, including chemotherapy, tyrosine kinase inhibitors, and emerging clinical trials.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- Up until a few years ago, there were no-FDA approved therapies for desmoid tumors. What was the role of chemotherapy and other pharmacotherapies like tyrosine kinase inhibitors in these patients? What is their role in current practice?
- What are the current NCCN guideline recommendations for treating desmoid tumors in patients?
- How do you utilize these in your daily practice?
- NCCN looks at surgery as a less preferred option vs. medication. How can this be incorporated into clinical practice, especially across specialties?
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5